Valeant shares tick higher as ear infection drug relaunched

Valeant Pharmaceuticals International Inc. shares ticked higher in the extended session Monday after the drug maker relaunched a bacterial ear infection treatment that had been discontinued last year. Valeant shares rose 0.7% to $22.60 after hours. The company said it was relaunching generic ofloxacin otic solution, after discontinuing the drug in April 2015 because of supplier problems.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.